UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Abstract P3-11-09: Not presented

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-11-09

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-04-28: A potential role for IL6ST mediating endocrine resistance in breast cancer via interaction with the ER signaling pathway

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-04-28

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-11-13: On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-11-13

2019

Link zum Volltext

Verfügbarkeit prüfen

Cyclin D1, Id1 and EMT in breast cancer

BMC cancer, 2011-09, Vol.11 (1), p.417-417, Article 417

2011

Link zum Volltext

Verfügbarkeit prüfen

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

BMC cancer, 2014-02, Vol.14 (1), p.119-119, Article 119

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-04-03: Molecular characterisation of ER+ breast cancer dormancy and acquired resistance using a clinical model: Potential involvement of epigenetic regulation

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-04-03

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-11-03: Measurement of on-treatment proliferation biomarkers in nodal metastasis improves prediction of endocrine therapy response using the EA2CliN test

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-11-03

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-03: EA2Clin: A novel immunohistochemical prognostic and predictive test for patients with estrogen receptor-Positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-08-03

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-04-27: Investigating the incidence of ESR1 gene amplification in breast cancers resistant to multiple endocrine agents

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-04-27

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-04-14: Tracking ESR1 mutation clonal evolution in breast cancer using in situ mutation detection

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-04-14

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-10-26: Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+ breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-10-26

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-18-03: A predictive model for local recurrence in patients treated for ductal carcinoma in situ of the breast (DCIS)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-18-03

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-06-04: Molecular characterisation, subtype concordance and prognostic group assignment between patient-matched primary breast tumours and axillary lymph node metastases

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-06-04

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-04-02: Characterising the effects of neoadjuvant endocrine therapy on primary cancers and nodal metastasis

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-04-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-02: Understanding the mechanisms of action underlying the role of IL6ST, a key biomarker for prediction of response to endocrine therapy

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-08-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-11-02: Predicting local recurrence in patients treated for ductal carcinoma in situ of the breast (DCIS)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-11-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-03-01: Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-03-01

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-06-17: Unlocking the transcriptomic potential of formalin-fixed paraffin embedded breast cancer tissues for high-throughput genomic analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-06-17

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-09-27: The EA2clin test significantly predicts response and survival in both pre and post-menopausal women with ER-positive breast cancers

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-09-27

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-07-20: A validated test for neoadjuvant clinical response to endocrine therapy in breast cancer that estimates accurately recurrence-free and overall survival

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-20

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-09-01: Comprehensive gene assessment of estrogen receptor positive breast cancer reveals that HER2 plays an important role in resistance to neoadjuvant letrozole

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P5-P5-09-01

2013

Link zum Volltext

Verfügbarkeit prüfen

Transcriptome Analysis of Recombinant Protein Secretion by Aspergillus nidulans and the Unfolded-Protein Response In Vivo

Applied and Environmental Microbiology, 2005-05, Vol.71 (5), p.2737-2747

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-04-09: Lack of response to aromatase inhibitors involves distinct mechanisms

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-04-09

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-05-05: Molecular effects of initial core biopsies in neoadjuvant window studies

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-05-05

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD3-2: Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.PD3-2-PD3-2

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(64)

Publikationsform

Sprache

Englisch
(65)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(24)
Humans
(14)
Female
(11)
Adult
(8)
Biological And Medical Sciences
(8)
Male
(7)
Middle Aged
(6)
Breast Cancer
(5)
Genetics
(5)
Genetics & Heredity
(5)
Physical Sciences
(5)
Aspergillus Nidulans
(4)
Diagnosis
(4)
Extraterrestrial Geology
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Gene Expression
(4)
Mars
(4)
Mars Exploration Rover
(4)
Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract P3-11-09: Not presented

Abstract P5-04-28: A potential role for IL6ST mediating endocrine resistance in breast cancer via interaction with the ER signaling pathway

Abstract P3-11-13: On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer

Cyclin D1, Id1 and EMT in breast cancer

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

Abstract P5-04-03: Molecular characterisation of ER+ breast cancer dormancy and acquired resistance using a clinical model: Potential involvement of epigenetic regulation

Abstract P5-11-03: Measurement of on-treatment proliferation biomarkers in nodal metastasis improves prediction of endocrine therapy response using the EA2CliN test

Abstract P4-08-03: EA2Clin: A novel immunohistochemical prognostic and predictive test for patients with estrogen receptor-Positive breast cancer

Abstract P5-04-27: Investigating the incidence of ESR1 gene amplification in breast cancers resistant to multiple endocrine agents

Abstract P5-04-14: Tracking ESR1 mutation clonal evolution in breast cancer using in situ mutation detection

Abstract P3-10-26: Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+ breast cancer

Abstract P5-18-03: A predictive model for local recurrence in patients treated for ductal carcinoma in situ of the breast (DCIS)

Abstract P1-06-04: Molecular characterisation, subtype concordance and prognostic group assignment between patient-matched primary breast tumours and axillary lymph node metastases

Abstract P4-04-02: Characterising the effects of neoadjuvant endocrine therapy on primary cancers and nodal metastasis

Abstract P4-08-02: Understanding the mechanisms of action underlying the role of IL6ST, a key biomarker for prediction of response to endocrine therapy

Abstract P5-11-02: Predicting local recurrence in patients treated for ductal carcinoma in situ of the breast (DCIS)

Abstract P4-03-01: Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers

Abstract P3-06-17: Unlocking the transcriptomic potential of formalin-fixed paraffin embedded breast cancer tissues for high-throughput genomic analysis

Abstract P6-09-27: The EA2clin test significantly predicts response and survival in both pre and post-menopausal women with ER-positive breast cancers

Abstract P3-07-20: A validated test for neoadjuvant clinical response to endocrine therapy in breast cancer that estimates accurately recurrence-free and overall survival

Abstract P5-09-01: Comprehensive gene assessment of estrogen receptor positive breast cancer reveals that HER2 plays an important role in resistance to neoadjuvant letrozole

Transcriptome Analysis of Recombinant Protein Secretion by Aspergillus nidulans and the Unfolded-Protein Response In Vivo

Abstract P6-04-09: Lack of response to aromatase inhibitors involves distinct mechanisms

Abstract P4-05-05: Molecular effects of initial core biopsies in neoadjuvant window studies

Abstract PD3-2: Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment

Suchergebnisse filtern